Loading...
•
Mar 31, 2020
Organogenesis Q1 2020 Earnings Report
Organogenesis reported financial results for the first quarter of 2020.
Key Takeaways
Organogenesis Holdings Inc. reported an 8% increase in net revenue for the first quarter of 2020, reaching $61.7 million compared to $57.1 million in the first quarter of 2019. The company experienced a net loss of $16.3 million, slightly higher than the $15.7 million loss in the same period last year. The increase in revenue was driven by growth in both Advanced Wound Care and Surgical & Sports Medicine products.
Net revenue increased by 8% to $61.7 million compared to Q1 2019.
Advanced Wound Care products revenue increased by 7% to $51.3 million.
Surgical & Sports Medicine products revenue increased by 13% to $10.4 million.
Net loss was $16.3 million, compared to a net loss of $15.7 million for the first quarter of 2019.
Organogenesis
Organogenesis
Organogenesis Revenue by Segment
Revenue by Segment
Advanced Wound Care Revenue
CapyFin.comSurgical & Sports Medicine Revenue
CapyFin.com Forward Guidance
The Company withdrew its previously announced fiscal year 2020 revenue guidance, originally issued on March 9, 2020, due to the rapidly evolving environment and uncertainty resulting from the impact of the COVID-19 pandemic. Given continued uncertainty, the Company is currently unable to predict the impact that COVID-19 will have on its financial position and operating results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income